8-K: Supernus Pharmaceuticals Reports First Quarter 2025 Financial Results; Qelbree Sales Surge 44%

Supernus Pharmaceuticals announces its first quarter 2025 financial results, highlighting a 4% increase in total revenues to $149.8 million and a 44% increase in Qelbree net sales.

Summary

• Supernus Pharmaceuticals reported a 4% increase in total revenues for the first quarter of 2025, reaching $149.8 million.
• Qelbree net sales increased by 44% to $64.7 million compared to the same period in 2024.
• GOCOVRI net sales increased by 16% to $30.7 million compared to the first quarter of 2024.
• Excluding Trokendi XR and Oxtellar XR, total revenues increased by 26% compared to the first quarter of 2024.
• The company reported an operating loss of $(10.3) million for the first quarter of 2025, compared to an operating loss of $(3.2) million in 2024.
• Adjusted operating earnings increased by 16% to $25.9 million for the first quarter of 2025.
• ONAPGO was launched in the U.S. in April 2025.
• The company reiterated its full-year 2025 financial guidance, projecting total revenues between $600 million and $630 million.
• Combined R&D and SG&A expenses are expected to be between $435 million and $460 million.
• The company anticipates an operating loss between $(15) million and $10 million, and adjusted operating earnings between $105 million and $130 million.
• Cash, cash equivalents, and marketable securities were approximately $463.6 million as of March 31, 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to strong growth in key products like Qelbree and GOCOVRI, the launch of ONAPGO, and reiterated financial guidance. However, the operating loss and decline in sales of older products temper the overall outlook.

Positives

• Qelbree sales are up 44%, indicating strong market adoption.
• GOCOVRI sales increased by 16%, showing continued growth.
• The launch of ONAPGO provides a new revenue stream and growth opportunity.
• The company has a strong cash position of $463.6 million.
• Total IQVIA prescriptions for Qelbree were 214,908 for the first quarter 2025, an increase of 22% compared to the same period in the prior year.

Negatives

• The company experienced an operating loss of $(10.3) million in Q1 2025, compared to a loss of $(3.2) million in Q1 2024.
• Net loss and diluted loss per share were $(11.8) million and $(0.21) for the three months ended March 31, 2025, compared to net earnings and diluted earnings per share of $0.1 million and $0.00 for the three months ended March 31, 2024.
• Sales of Trokendi XR and Oxtellar XR decreased significantly, impacting overall revenue growth.

Risks

• The company's ability to sustain and increase its profitability is subject to various risks and uncertainties.
• The company's ability to raise sufficient capital to fully implement its corporate strategy is a risk.
• The company's future financial performance and projected expenditures are subject to risks and uncertainties.
• The company's ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others is a risk.
• The company's expectations regarding federal, state and foreign regulatory requirements are subject to risks and uncertainties.

Future Outlook

The company reiterates its full-year 2025 financial guidance, projecting total revenues between $600 million and $630 million, combined R&D and SG&A expenses between $435 million and $460 million, an operating loss between $(15) million and $10 million, and adjusted operating earnings between $105 million and $130 million.

Management Comments

• Our first quarter results reflect, once again, double-digit revenue growth from our core products, as well as strong growth in adjusted operating earnings, said Jack Khattar, President and CEO of Supernus.
• In addition, we are pleased to be bringing ONAPGO to market, another growth driver for our business.
• ONAPGO represents a novel approach for adults with Parkinsons disease who are experiencing motor fluctuations.

Industry Context

Supernus's focus on CNS diseases aligns with the growing need for treatments in this area, and the launch of ONAPGO addresses a specific unmet need in Parkinson's disease. The company's performance is being driven by key products like Qelbree and GOCOVRI, which are experiencing solid growth in competitive markets.

Comparison to Industry Standards

• Supernus's revenue growth in Qelbree (44%) is strong compared to other ADHD medications, suggesting effective market penetration.
• The launch of ONAPGO positions Supernus competitively against other treatments for motor fluctuations in Parkinson's disease, such as those offered by AbbVie (Duopa) and Acorda Therapeutics (Inbrija).
• The company's cash position of $463.6 million provides a solid foundation for continued R&D and commercialization efforts, comparable to other mid-sized biopharmaceutical companies.

Stakeholder Impact

• Shareholders: The results provide mixed signals, with strong product growth offset by an operating loss.
• Employees: The company's growth and new product launches could lead to job security and potential opportunities.
• Customers: The launch of ONAPGO provides a new treatment option for Parkinson's disease patients.
• Suppliers: Increased sales of key products could lead to higher demand for raw materials and manufacturing services.

Next Steps

• Continue the Phase 2b study of SPN-817 for epilepsy.
• Initiate a Phase 2b trial of SPN-820 for depression.
• Disclose a lead indication for SPN-443 by the end of 2025.

Key Dates

Keywords

Supernus Pharmaceuticals, Financial Results, Qelbree, GOCOVRI, ONAPGO, CNS Diseases, Revenue, Earnings, Pharmaceuticals